Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00773409 · ClinicalTrials.gov registry record
Evaluation of the Risk of Nephrogenic Systemic Fibrosis (NSF) in Patients With Chronic Kidney Disease Without Exposure to Gadolinium Based Contrast Agents (GBCA)
A clinical trial of Renal Insufficiency, sponsored by Bracco Diagnostics.
- Completed
- Registry status
- 405
- Enrollment target
- 1
- Study location
NCT00773409 is a study of Renal Insufficiency that has completed, run by Bracco Diagnostics. The registered enrollment target is 405 participants, above the 83-participant average among 22 other Renal Insufficiency trials with a reported enrollment target (388% higher). The trial reports 1 study location across 1 state.
The verdict
NCT00773409, a study of Renal Insufficiency, has completed, sponsored by Bracco Diagnostics.
- COMPLETED
- Registry status
- 405 participants
- Enrollment target
- 1
- Study location
Study Summary
The objective of this long term study is to prospectively evaluate the incidence of NSF in patients with severe CKD or kidney failure including patients undergoing dialysis (stages 4 and 5 i.e., with an eGFR below 30)who have not had exposure to a GBCA within 10 years prior to enrollment.
Conditions Studied
Study Locations (1)
New Jersey
- Bracco Diagnostics Inc. - Princeton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 405 participants |
| Start Date | 2008-10 |
| Est. Completion | 2012-07 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00773409
The ClinicalTrials.gov registry entry for NCT00773409 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 405 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 83-participant average among 22 other Renal Insufficiency trials with a reported enrollment target (388% higher). The listed sponsor is Bracco Diagnostics, which has 37 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Renal Insufficiency appearing as the primary indexed condition, and to 0 interventions.
NCT00773409 reports 1 study location spanning 1 distinct geographic area - top geographies include New Jersey.
Frequently Asked Questions
What is clinical trial NCT00773409 about?
NCT00773409 is a clinical study titled "Evaluation of the Risk of Nephrogenic Systemic Fibrosis (NSF) in Patients With Chronic Kidney Disease Without Exposure to Gadolinium Based Contrast Agents (GBCA)". The objective of this long term study is to prospectively evaluate the incidence of NSF in patients with severe CKD or kidney failure including patients undergoing dialysis (stages 4 and 5 i.e., with an eGFR below 30)who have not had exposure to a GBCA within 10 years prior to enrollment.
What is the current status of trial NCT00773409?
This trial is currently completed. The enrollment target is 405 participants. The study started on 2008-10. Estimated completion is 2012-07.
What conditions does trial NCT00773409 study?
This clinical trial studies the following conditions: Renal Insufficiency.
Who is sponsoring clinical trial NCT00773409?
This trial is sponsored by Bracco Diagnostics, which has 37 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00773409 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Renal Insufficiency
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
SAVE-FistulaS: the SelfWrap-Assisted ArterioVEnous Fistulas Study
RECRUITING · NA
-
A Study of LY3537982 in Participants With Kidney Problems Compared With Participants With Normal Kidney Function
RECRUITING · Phase 1
-
A Study of Eloralintide (LY3841136) in Participants With Renal Impairment and in Participants With Normal Renal Function
RECRUITING · Phase 1
-
A Study of Pharmacokinetics and Safety of LY3537031 in Participants With Normal Renal Function and Participants With Renal Impairment
ACTIVE NOT RECRUITING · Phase 1
-
A Study to Assess the Pharmacokinetics of CC-122 in Subjects With Mild, Moderate, and Severe Renal Impairment
COMPLETED · Phase 1
-
"Pharmacokinetic Study of Fondaparinux in Inpatients With Renal Dysfunction"
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.